CHMP Issues Positive Opinion For Once-Daily Prezista(R) (Darunavir) As Part Of Combination Therapy For Treatment-Naïve Adults With HIV-1

The Committee for Human Medicinal Products (CHMP) has issued a positive opinion recommending approval for once-daily dosing of 800 mg PREZISTA® (darunavir) with low-dose ritonavir as part of combination therapy in treatment-naïve adults (those who have never taken HIV medication before). Darunavir, a protease inhibitor, was developed by Tibotec Pharmaceuticals, and Tibotec, a division of Janssen-Cilag, is the organisation responsible for marketing the brand in Europe.

More: continued here

Filed under: HIV / AIDS on December 2nd, 2008